Neurological Toxicity Recognition: ICANS Assessment and Management

EP: 1.ES-SCLC vs LS-SCLC: Critical Differences in Disease Burden and Patient Prognosis

EP: 2.Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLC

EP: 3.Addressing Critical Unmet Needs in ES-SCLC Patient Management

EP: 4.Emerging Clinical Trials: Novel Approaches in Second-Line ES-SCLC

EP: 5.Institutional Implementation: Setting Up Tarlatamab Administration

EP: 6.Optimizing Multidisciplinary Coordination for Successful Tarlatamab Implementation

EP: 7.Patient Selection Criteria: Identifying Appropriate Candidates for Tarlatamab

EP: 8.Tarlatamab Administration and Postinfusion Monitoring

EP: 9.Essential Patient and Caregiver Education for Tarlatamab Treatment Success

Now Viewing

EP: 10.Neurological Toxicity Recognition: ICANS Assessment and Management

EP: 11.CRS Recognition and Intervention: Timing and Clinical Features

EP: 12.Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue

EP: 13.Differential Toxicity Profile: Tarlatamab vs Traditional Cytotoxic Therapies

EP: 14.Standardized Toxicity Grading: Institutional Protocols for CRS and ICANS

EP: 15.Future Research Priorities: Optimizing Tarlatamab Administration and Toxicity Management

EP: 16.Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum

EP: 17.Complex ES-SCLC Case: Tarlatamab Management Through Toxicity to Clinical Benefit

Summary for Physicians:

Neurological Toxicity: Immune Effector Cell–Associated Neurotoxicity Syndrome (ICANS) Assessment and Management

• ICANS (Immune-Related Neurotoxicity):
• Can range from mild symptoms (eg, confusion, agitation) to severe effects (eg, encephalopathy, seizures).

• Assessment includes evaluating mental status, motor function, speech, and level of consciousness.
• Grading ICANS:
• Grade 1: Mild symptoms, no intervention needed

• Grade 2: Moderate symptoms, requires intervention (eg, corticosteroids)

• Grade 3: Severe symptoms, may need intensive care unit admission and aggressive treatment

• Grade 4: Life-threatening symptoms, requires urgent intervention
• Management:
• Mild (grade 1): Supportive care, close monitoring

• Moderate to severe (grade 2-4):

• Administer steroids (eg, dexamethasone) to manage inflammation.

• For grade 3/4, consider immunosuppressive therapy and intensive neurological monitoring.

• Prompt recognition is critical for preventing progression.

Challenges:

Early detection and rapid intervention are key to minimizing long-term neurological impact.